Neoplastic tumours are known to promote immune tolerance, which can lead to chemotherapy resistance. New insights into the underlying mechanisms are provided by a study in Nature
(online, 29 April 2015), which shows that mouse models of aggressive prostate cancer are resistant to the chemotherapy drug oxaliplatin unless the animals are lacking immunosuppressive B cells.
When B cells were depleted – either genetically or pharmacologically – the prostate tumours became susceptible to treatment with oxaliplatin. “The crucial immunosuppressive B cells are plasmocytes that express IgA, interleukin-10 and programmed death ligand 1,” the authors write.
Since immunosuppressive B-cells are also known to infiltrate human treatment-resistant prostate cancers, this is a promising line of research for novel cancer therapies, they say.